The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Arcus Biosciences Inc | COM | 03969F109 | 18,605 | 1,842,077 | SH | SOLE | 1,842,077 | 0 | 0 | ||
| Novocure Ltd | ORD SHS | G6674U108 | 39,681 | 470,884 | SH | SOLE | 470,884 | 0 | 0 | ||
| Oyster Point Pharma Inc | COM | 69242L106 | 63,300 | 2,590,015 | SH | SOLE | 2,590,015 | 0 | 0 | ||
| Unity Biotechnology Inc | COM | 91381U101 | 15,790 | 2,189,998 | SH | SOLE | 2,189,998 | 0 | 0 | ||
| Yext Inc | COM | 98585N106 | 59,797 | 4,146,784 | SH | SOLE | 4,146,784 | 0 | 0 | ||